When considering his first CEO role, Baldo strategically chose one that combined his passion for ophthalmology, a strong investor syndicate, promising clinical data, and a Phase 3 asset. This matched his self-identified "sweet spot" in late-stage drug development, creating an ideal entry point into a C-suite position.
Related Insights
A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.
To build a resilient team during a tough economic period, CEO Sean Ainsworth prioritized finding people who deeply understood the 'why' behind the science and its patient impact. This created a committed core team that could navigate funding challenges when capital was scarce for unproven gene therapies.
In Biotech, risk is removed pre-FDA approval via clinical trials, making a Chief Development Officer (clinical, regulatory, manufacturing) the most critical hire. In many MedTech sectors, risk is removed post-FDA approval via market adoption, making a Chief Commercial Officer paramount.
The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.
To find a Chief Scientific Officer with a rare combination of skills, EARLI's CEO used LinkedIn search. He combined terms like "gene therapy," "venture," and "FDA experience" to narrow the global candidate pool to about 25 people, proving precise digital sourcing can outperform traditional networking for highly specialized roles.
Baldo was training to be an orthopedic surgeon but pivoted after co-founding a venture-backed medical software company. He faced a clear inflection point and made a conscious decision to forgo completing his medical training to remain in business, highlighting that successful executive career paths are not always linear.
The founder hired an experienced CEO and then rotated through leadership roles in different departments (brand, product, tech). This created a self-designed, high-stakes apprenticeship, allowing him to learn every facet of the business from experts before confidently retaking the CEO role.
The CEO's journey began with a personal obsession to fix what he saw as a great but poorly-run public company. He even researched a take-private deal as a "hobby" before being contacted for the role. This demonstrates that deep, unsolicited strategic analysis of a public company's flaws can be a direct path to its leadership.
The CEO of Peptilogics boils down leadership in the unpredictable, long-haul life sciences industry to three traits. Leaders must adapt to rapid changes, maintain a steady hand for the decade-plus development cycles, and provide a clear, guiding vision throughout.
The ambition to be a CEO isn't just about leadership; it's a practical blend of ego, a need for control, and financial motivation. Critically, it stems from a deep-seated belief in one's own judgment and risk appetite, especially during pivotal market shifts that require bold, swift action.
